Pfizer — Morgan Stanley 2013 R&D Seminar: Reigniting Pharma

6 slides from Pfizer's conference presentation, May 10, 2013

Slide 1: Pfizer R&D Overview
Pfizer R&D Overview Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D May 10, 2013
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discu
Slide 3: Continue to Execute on a Multi-year R&D Turnaround
Continue to Execute on a Multi-year R&D Turnaround Lay the Drive the Deliver a Sustainable Foundation Transformation Flow of Innovative Shift to more value on Therapies Interrogate and change the Pfizer R&D model lower cost base R&D delivers clear ROI 2010 • Increased focus and rigor in • Execute on
Slide 4: Strong Pipeline Momentum
Strong Pipeline Momentum Pipeline Snapshot as of May 9, 2013 Discovery Projects Phase 1 Phase 2 Phase 3 In Reg. Total 25 25 18 6 74 Recent Approvals 4
Slide 5: Highlights from the Mid-to-Late Stage Portfolio
Highlights from the Mid-to-Late Stage Portfolio Key Next Wave Programs Key Late Stage Programs Xeljanz Xeljanz Crohn’s, Ankylosing Spondylitis Phase 3 studies in Ulcerative Colitis & Psoriasis IL6, Anti-MAdCAM, Oral P38 Eliquis Chronic Inflammatory Diseases VTE Treatment & Prevention SMO, PI3K mTOR
Slide 6: Q&A
Q&A